To properly treat prostate cancer, patients should undergo full evaluation, including DRE, checking PSA and LFT, life expectancy and comorbidity evaluation, abdominal-pelvic CT, MRI and radionuclide bone scans if needed, and based on these data and characterizations of tumor (Table 2), including clinical stage, Gleason score, tumor volume, invasion and metastasis, patients are stratified into low, intermediate, high and very high risk groups and the cancer divided to localized, locally advance and metastatic prostate cancer [80,81,82]. This evidence concerns the gene KLK3 and prostate carcinoma.